
Indicated for the detection and visualization of abnormal vascularity in the central nervous system (CNS) and non-CNS body regions, gadoquatrane provides 60 percent less gadolinium dosing in comparison to other macrocyclic gadolinium (Gd)-based contrast agents (mGBCAs).




























